Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia

Journal of Clinical Oncology

Volumn 29, Issue 9, 2011, Pages 1190-1197

  Walter, Roland B ^a   Gooley, Ted A ^a   Wood, Brent L ^a   Milano, Filippo ^a   Fang, Min ^a   Sorror, Mohamed L ^a   Estey, Elihu H ^a   Salter, Alexander I ^a   Lansverk, Emily ^a   Chien, Jason W ^a   Gopal, Ajay K ^a   Appelbaum, Frederick R ^a   Pagel, John M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CYTOGENETICS; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MINIMAL RESIDUAL DISEASE; MULTIPARAMETRIC FLOW CYTOMETRY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 79952757082     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.8121     Document Type: Article

References (33)

1. Koreth J, Schlenk R, Kopecky KJ, et al: Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA 301:2349-2361, 2009
2. Cornelissen JJ, van Putten WL, Verdonck LF, et al: Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom? Blood 109:3658-3666, 2007
3. Yanada M, Matsuo K, Emi N, et al: Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: A meta analysis. Cancer 103:1652-1658, 2005 (Pubitemid 40490026)
4. Wheatley K, Gray R: Commentary: Mendelian randomization: An update on its use to evaluate allogeneic stem cell transplantation in leukaemia. Int J Epidemiol 33:15-17, 2004 (Pubitemid 38500148)
5. Appelbaum FR, Pearce SF: Hematopoietic cell transplantation in first complete remission versus early relapse. Best Pract Res Clin Haematol 19:333-339, 2006
6. Lodewyck T, Cornelissen JJ: Allogeneic stem cell transplantation in acute myeloid leukemia: A risk-adapted approach. Blood Rev 22:293-302, 2008
7. Craig FE, Foon KA: Flow cytometric immunophenotyping for hematologic neoplasms. Blood 111:3941-3967, 2008
8. Kern W, Haferlach C, Haferlach T, et al: Monitoring of minimal residual disease in acute myeloid leukemia. Cancer 112:4-16, 2008
9. Al-Mawali A, Gillis D, Lewis I: The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol 131:16-26, 2009
10. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937-951, 2009
11. Mrózek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 18:115-136, 2004 (Pubitemid 38380667)
12. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
13. Sorror ML, Maris MB, Storb R, et al: Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106:2912-2919, 2005 (Pubitemid 41510773)
14. Sorror ML, Giralt S, Sandmaier BM, et al: Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: Combined FHCRC and MDACC experiences. Blood 110:4606-4613, 2007 (Pubitemid 351377830)
15. Parimon T, Au DH, Martin PJ, et al: A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 144:407-414, 2006 (Pubitemid 46768162)
16. Wood B: 9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 130:680-690, 2006
17. Wood BL: Ten-color immunophenotyping of hematopoietic cells. Curr Protoc Cytom 6:21.1-21.11, 2005
18. Wood BL: Myeloid malignancies: Myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia. Clin Lab Med 27:551-575, 2007
19. Shook D, Coustan-Smith E, Ribeiro RC, et al: Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma 9:S281-S285, 2009 (suppl 3)
20. San Miguel JF, Martínez A, Macedo A, et al: Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 90:2465-2470, 1997 (Pubitemid 27392732)
21. San Miguel JF, Vidriales MB, López-Berges C, et al: Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98:1746-1751, 2001
22. Venditti A, Buccisano F, Del Poeta G, et al: Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 96:3948-3952, 2000
23. Sievers EL, Lange BJ, Alonzo TA, et al: Immunophenotypic evidence of leukemia after induction therapy predicts relapse: Results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 101:3398-3406, 2003 (Pubitemid 36857920)
24. Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al: Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 123:243-252, 2003 (Pubitemid 37305058)
25. Perea G, Lasa A, Aventín A, et al: Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 20:87-94, 2006
26. Langebrake C, Creutzig U, Dworzak M, et al: Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: The MRD-AML-BFM Study Group. J Clin Oncol 24:3686-3692, 2006 (Pubitemid 46630545)
27. Maurillo L, Buccisano F, Del Principe MI, et al: Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 26:4944-4951, 2008
28. Laane E, Derolf AR, Björklund E, et al: The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica 91:833-836, 2006 (Pubitemid 44014555)
29. Díez-Campelo M, Pérez- Simón JA, Pérez J, et al: Minimal residual disease monitoring after allogeneic transplantation may help to individualize posttransplant therapeutic strategies in acute myeloid malignancies. Am J Hematol 84:149-152, 2009
30. Walter RB, Pagel JM, Gooley TA, et al: Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia 24:1276-1282, 2010
31. Tallman MS, Rowlings PA, Milone G, et al: Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 96:1254-1258, 2000 (Pubitemid 30658451)
32. Cahn JY, Labopin M, Sierra J, et al: No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission: Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110:308-314, 2000 (Pubitemid 30646855)
33. Sproat L, Bolwell B, Rybicki L, et al: Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission. Leuk Lymphoma 51:1699-1704, 2010